(TALS)


Exchange


Currency in (Disclaimer)
Volume:
Day's Range:

TALS Insider Transactions

Transaction Date
(SEC Report )
Reporting Name Relationship Shrs. Owned Type Acq./Disp. Shrs. Transacted Price() Amount()
2023-03-17 Ildstad Suzanne director 3,054,124 S-Sale D 10,436 2.06 21,543.03
2023-03-03 Ildstad Suzanne director 3,064,560 S-Sale D 6,806 2.06 13,992.46
2023-03-01 Ildstad Suzanne director 3,071,366 S-Sale D 29 2.05 59.45
2023-02-21 Ildstad Suzanne director 3,071,395 S-Sale D 3,500 2.05 7,185.15
2023-02-17 Ildstad Suzanne director 3,074,895 S-Sale D 3,612 2.05 7,405.68
2023-02-16 Ildstad Suzanne director 3,078,507 S-Sale D 2,939 2.06 6,039.94
2023-02-01 Fenton Mary Kay officer: Chief Financial Officer 150,000 A-Award A 150,000 1.73 259,500.00
2023-02-01 Fenton Mary Kay officer: Chief Financial Officer 150,000 A-Award A 150,000 1.73 259,500.00
2023-02-01 Krieger Nancy officer: Chief Medical Officer 120,000 A-Award A 120,000 1.73 207,600.00
2023-02-01 Krieger Nancy officer: Chief Medical Officer 120,000 A-Award A 120,000 1.73 207,600.00
2023-02-01 Requadt Scott director, officer: Chief Executive Officer 320,000 A-Award A 320,000 1.73 553,600.00
2023-02-01 Requadt Scott director, officer: Chief Executive Officer 320,000 A-Award A 320,000 1.73 553,600.00
2023-02-01 Zdanowski Michael officer: Chief Technology Officer 150,000 A-Award A 150,000 1.73 259,500.00
2023-02-01 Zdanowski Michael officer: Chief Technology Officer 150,000 A-Award A 150,000 1.73 259,500.00
2022-12-30 Requadt Scott director, officer: Chief Executive Officer 590,193 A-Award A 4 0.87 3.47
2022-09-10 Zdanowski Michael officer: Chief Technology Officer 121,470 A-Award A 120,000 0.00 0.00
2022-09-10 Fenton Mary Kay officer: Chief Financial Officer 81,000 A-Award A 80,000 0.00 0.00
2022-09-10 Requadt Scott director, officer: Chief Executive Officer 590,189 A-Award A 80,000 0.00 0.00
2022-09-10 Krieger Nancy officer: Chief Medical Officer 330,233 A-Award A 80,000 0.00 0.00
2022-08-22 Ildstad Suzanne officer: Chief Scientific Officer 3,081,446 S-Sale D 525,000 2.80 1,470,000.00
2022-07-29 Requadt Scott director, officer: Chief Executive Officer 508,680 P-Purchase A 39,382 4.25 167,373.50
2022-07-28 Requadt Scott director, officer: Chief Executive Officer 469,298 P-Purchase A 3,090 4.25 13,132.50
2022-07-26 Requadt Scott director, officer: Chief Executive Officer 466,208 P-Purchase A 5,528 4.24 23,438.72
2022-07-25 Nader Francois director 386,932 J-Other A 138,500 0.00 0.00
2022-07-25 Nader Francois director 0 J-Other D 138,500 0.00 0.00
2022-07-22 Requadt Scott director, officer: Chief Executive Officer 460,680 P-Purchase A 9,444 3.75 35,412.17
2022-07-21 Nader Francois director 138,500 P-Purchase A 36,500 3.72 135,780.00
2022-07-21 Nader Francois director 248,432 J-Other A 248,432 0.00 0.00
2022-07-21 Nader Francois director 147,255 J-Other D 248,432 0.00 0.00
2022-07-21 Nader Francois director 87,735 J-Other D 248,432 0.00 0.00
2022-07-20 Nader Francois director 102,000 P-Purchase A 52,000 3.62 188,240.00
2022-07-19 Nader Francois director 50,000 P-Purchase A 50,000 3.52 176,000.00
2022-06-09 MCDADE MARK director 14,501 A-Award A 14,501 8.45 122,533.45
2022-06-09 MACKAY GEOFFREY director 14,501 A-Award A 14,501 8.45 122,533.45
2022-06-09 Smith Karen L. director 14,501 A-Award A 14,501 8.45 122,533.45
2022-06-09 Shah Gaurav director 14,501 A-Award A 14,501 8.45 122,533.45
2022-06-09 Nader Francois director 14,501 A-Award A 14,501 8.45 122,533.45
2022-06-09 Srivastava Sapna director 14,501 A-Award A 14,501 8.45 122,533.45
2022-06-09 Agarwala Sandip director, 10 percent owner 14,501 A-Award A 14,501 8.45 122,533.45
2022-05-16 Smith Karen L. director 29,002 A-Award A 29,002 6.54 189,673.08
2022-02-01 Ildstad Suzanne officer: Chief Scientific Officer 150,000 A-Award A 150,000 9.10 1,365,000.00
2022-02-01 Zdanowski Michael officer: Chief Technology Officer 200,000 A-Award A 200,000 9.10 1,820,000.00
2022-02-01 Fenton Mary Kay officer: Chief Financial Officer 200,000 A-Award A 200,000 9.10 1,820,000.00
2022-02-01 Requadt Scott director, officer: Chief Executive Officer 500,000 A-Award A 500,000 9.10 4,550,000.00
2022-02-01 Krieger Nancy officer: Chief Medical Officer 190,000 A-Award A 190,000 9.10 1,729,000.00
2021-12-31 Zdanowski Michael officer: Chief Technology Officer 1,470 A-Award A 1,470 13.00 19,110.00
2021-12-31 Fenton Mary Kay officer: Chief Financial Officer 1,000 A-Award A 1,000 13.00 13,000.00
2021-12-31 Requadt Scott director, officer: Chief Executive Officer 451,236 A-Award A 1,470 13.00 19,110.00
2021-12-15 Nader Francois director 336,167 G-Gift D 59,520 0.00 0.00
2021-11-17 Ildstad Suzanne officer: Chief Scientific Officer 1,200,000 G-Gift A 1,200,000 0.00 0.00
2021-11-17 Ildstad Suzanne officer: Chief Scientific Officer 3,606,446 G-Gift D 1,200,000 0.00 0.00
2021-05-11 Clarus Defined Exit I, L.P. 10 percent owner 0 C-Conversion D 135,334 0.00 0.00
2021-05-11 Clarus Defined Exit I, L.P. 10 percent owner 0 C-Conversion D 135,334 0.00 0.00
2021-05-11 Clarus Defined Exit I, L.P. 10 percent owner 160,044 P-Purchase A 701 17.00 11,917.00
2021-05-11 Clarus Defined Exit I, L.P. 10 percent owner 665,676 P-Purchase A 2,917 17.00 49,589.00
2021-05-11 Clarus Defined Exit I, L.P. 10 percent owner 329,598 P-Purchase A 1,444 17.00 24,548.00
2021-05-11 Clarus Defined Exit I, L.P. 10 percent owner 823,997 P-Purchase A 3,611 17.00 61,387.00
2021-05-11 Clarus Defined Exit I, L.P. 10 percent owner 432,015 C-Conversion A 68,582 0.00 0.00
2021-05-11 Clarus Defined Exit I, L.P. 10 percent owner 662,759 C-Conversion A 105,213 0.00 0.00
2021-05-11 Clarus Defined Exit I, L.P. 10 percent owner 328,154 C-Conversion A 52,094 0.00 0.00
2021-05-11 Clarus Defined Exit I, L.P. 10 percent owner 557,546 C-Conversion A 557,546 0.00 0.00
2021-05-11 Clarus Defined Exit I, L.P. 10 percent owner 4,859,812 C-Conversion A 4,859,812 0.00 0.00
2021-05-11 Clarus Lifesciences III, L.P. 10 percent owner 0 C-Conversion D 135,334 0.00 0.00
2021-05-11 Clarus Lifesciences III, L.P. 10 percent owner 0 C-Conversion D 135,334 0.00 0.00
2021-05-11 Clarus Lifesciences III, L.P. 10 percent owner 0 C-Conversion D 135,334 0.00 0.00
2021-05-11 Clarus Lifesciences III, L.P. 10 percent owner 160,044 P-Purchase A 701 17.00 11,917.00
2021-05-11 Clarus Lifesciences III, L.P. 10 percent owner 800,353 P-Purchase A 3,507 17.00 59,619.00
2021-05-11 Clarus Lifesciences III, L.P. 10 percent owner 823,997 P-Purchase A 3,611 17.00 61,387.00
2021-05-11 Clarus Lifesciences III, L.P. 10 percent owner 820,386 C-Conversion A 130,236 0.00 0.00
2021-05-11 Clarus Lifesciences III, L.P. 10 percent owner 134,047 C-Conversion A 134,047 0.00 0.00
2021-05-11 Clarus Lifesciences III, L.P. 10 percent owner 690,150 C-Conversion A 690,150 0.00 0.00
2021-05-11 Clarus Lifesciences III, L.P. 10 percent owner 4,859,812 C-Conversion A 4,859,812 0.00 0.00
2021-05-11 Clarus Lifesciences III, L.P. 10 percent owner 670,347 C-Conversion A 670,347 0.00 0.00
2021-05-11 Clarus Lifesciences III, L.P. 10 percent owner 276,060 C-Conversion A 276,060 0.00 0.00
2021-05-11 Clarus Lifesciences III, L.P. 10 percent owner 363,433 C-Conversion A 363,433 0.00 0.00
2021-05-11 Clarus Defined Exit I, L.P. 10 percent owner 690,150 C-Conversion A 690,150 0.00 0.00
2021-05-11 Clarus Lifesciences III, L.P. 10 percent owner 557,546 C-Conversion A 557,546 0.00 0.00
2021-05-11 Clarus Lifesciences III, L.P. 10 percent owner 433,917 P-Purchase A 1,902 17.00 32,334.00
2021-05-11 Clarus Lifesciences III, L.P. 10 percent owner 665,676 P-Purchase A 2,917 17.00 49,589.00
2021-05-11 Clarus Defined Exit I, L.P. 10 percent owner 670,347 C-Conversion A 670,347 0.00 0.00
2021-05-11 Clarus Defined Exit I, L.P. 10 percent owner 0 C-Conversion D 135,334 0.00 0.00
2021-05-11 Agarwala Sandip 0 C-Conversion D 1,308,410 0.00 0.00
2021-05-11 Agarwala Sandip 3,220,775 P-Purchase A 235,000 17.00 3,995,000.00
2021-05-11 Agarwala Sandip 2,985,775 C-Conversion A 2,985,775 0.00 0.00
2021-05-11 Longitude Capital Partners III, LLC 2,985,775 C-Conversion A 2,985,775 0.00 0.00
2021-05-11 Longitude Capital Partners III, LLC 0 C-Conversion D 1,308,410 0.00 0.00
2021-05-11 Longitude Capital Partners III, LLC 3,220,775 P-Purchase A 235,000 17.00 3,995,000.00
2021-05-11 Clarus Lifesciences III, L.P. 10 percent owner 328,154 C-Conversion A 52,094 0.00 0.00
2021-05-11 Clarus Lifesciences III, L.P. 10 percent owner 662,759 C-Conversion A 105,213 0.00 0.00
2021-05-11 Clarus Lifesciences III, L.P. 10 percent owner 432,015 C-Conversion A 68,582 0.00 0.00
2021-05-11 Clarus Lifesciences III, L.P. 10 percent owner 329,598 P-Purchase A 1,444 17.00 24,548.00
2021-05-11 Clarus Lifesciences III, L.P. 10 percent owner 4,875,730 P-Purchase A 15,918 17.00 270,606.00
2021-05-11 Clarus Lifesciences III, L.P. 10 percent owner 796,846 C-Conversion A 126,499 0.00 0.00
2021-05-11 Clarus Lifesciences III, L.P. 10 percent owner 159,343 C-Conversion A 25,296 0.00 0.00
2021-05-11 Clarus Defined Exit I, L.P. 10 percent owner 820,386 C-Conversion A 130,236 0.00 0.00
2021-05-11 Clarus Defined Exit I, L.P. 10 percent owner 796,846 C-Conversion A 126,499 0.00 0.00
2021-05-11 Clarus Defined Exit I, L.P. 10 percent owner 134,047 C-Conversion A 134,047 0.00 0.00
2021-05-11 Clarus Defined Exit I, L.P. 10 percent owner 159,343 C-Conversion A 25,296 0.00 0.00
2021-05-11 Clarus Defined Exit I, L.P. 10 percent owner 433,917 P-Purchase A 1,902 17.00 32,334.00
2021-05-11 Clarus Defined Exit I, L.P. 10 percent owner 800,353 P-Purchase A 3,507 17.00 59,619.00

Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Group doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Group or anyone involved with Discounting Cash Flows Group will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.